Leerink Partnrs Issues Optimistic Outlook for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Leerink Partnrs lifted their Q1 2025 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research note issued to investors on Monday, February 17th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $0.77 for the quarter, up from their previous forecast of $0.70. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences’ Q2 2025 earnings at $1.18 EPS, FY2027 earnings at $8.85 EPS and FY2029 earnings at $9.00 EPS.

Several other analysts have also recently commented on the company. Bank of America decreased their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. UBS Group raised their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Wedbush decreased their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, Canaccord Genuity Group decreased their target price on Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $166.90.

Neurocrine Biosciences Stock Up 0.3 %

Shares of Neurocrine Biosciences stock opened at $114.26 on Thursday. The stock has a market cap of $11.39 billion, a PE ratio of 34.73, a price-to-earnings-growth ratio of 0.78 and a beta of 0.33. The business has a fifty day simple moving average of $136.97 and a 200-day simple moving average of $129.81. Neurocrine Biosciences has a 12 month low of $110.95 and a 12 month high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors have recently made changes to their positions in NBIX. Vanguard Group Inc. grew its position in Neurocrine Biosciences by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock worth $1,381,331,000 after buying an additional 122,681 shares in the last quarter. State Street Corp grew its position in Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after buying an additional 539,936 shares in the last quarter. Dodge & Cox grew its position in Neurocrine Biosciences by 134.2% during the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after buying an additional 1,728,605 shares in the last quarter. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 2.9% during the fourth quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company’s stock worth $258,926,000 after buying an additional 53,610 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Neurocrine Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock worth $255,523,000 after buying an additional 15,830 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 2,707 shares of Neurocrine Biosciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $152.92, for a total value of $413,954.44. Following the transaction, the director now directly owns 517,030 shares in the company, valued at approximately $79,064,227.60. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 236,600 shares of company stock worth $34,348,261 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.